In response to this need, Yonesaka et al. explored the combination of an EGFR small molecule inhibitor (osimertinib) and the HER3 antibody drug conjugate Patritumab-Deruxtecan (HER3-DXd) in patients with EGFR mutated cancer [127]. Here, ERBB3 is linked to cancer.